ArticleMolecular biology reports2025
Evaluating the influence of oleic and palmitic acids on inflammatory markers and gut barrier integrity in a celiac disease Caco-2 model.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe fatty acid (FA) composition of the gluten-free diet (GFD) may affect mucosal responses in celiac disease (CeD). This study evaluated the effects of oleic acid (OA) and palmitic acid (PA) on gliadin-induced inflammation and barrier dysfunction using Caco-2 cells.
methodsCaco-2 cells were cultured under standard conditions and exposed to peptic-tryptic digested gliadin (PT-Gliadin) to induce a CeD-like response. Cells were treated with OA or PA under three conditions: co-treatment (with PT-Gliadin), pre-treatment (before PT-Gliadin), or post-treatment (after PT-Gliadin). Inflammatory gene expression (NF-κB, TNF-α, IL-6, IL-15) and tight junction markers (ZO-1, occludin) were quantified by qRT-PCR, while IL-6 and IL-15 secretion was measured by ELISA.
resultsPT-Gliadin significantly increased inflammatory gene expression and cytokine secretion, while reducing ZO-1 and occludin levels (p < 0.05). OA co-treatment significantly suppressed NF-κB, TNF-α, IL-6, and IL-15 expression, lowered IL-6 and IL-15 secretion, and increased ZO-1 and occludin levels (p < 0.05). OA post-treatment also reduced NF-κB and IL-15 expression (p < 0.05) and diminished both IL-6 and IL-15 release (p < 0.05). Conversely, PA co-treatment elevated NF-κB, TNF-α, IL-6, and IL-15 expression (p < 0.05), increased IL-6 secretion (p < 0.05), and aggravated the loss of ZO-1 and occludin (p < 0.05). PA post-treatment similarly enhanced NF-κB, TNF-α, IL-6, and IL-15 expression (p < 0.05), increased IL-6 secretion (p < 0.05), and reduced occludin level (p < 0.05). Pre-treatment with either FA produced no significant effects.
conclusionOA mitigates, whereas PA exacerbates, gliadin-induced inflammation and barrier damage in Caco-2 cells. Modifying GFD fat composition to favor OA over PA may improve mucosal outcomes in CeD.
Indexed as
Identifiers
40982164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.